Add to ORKGPhase II study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including post myeloproliferative neoplasms (MPN) acute myeloid leukemia (AML
JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cyt...
JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cyt...
Item does not contain fulltextBACKGROUND: Protein kinase C beta (PKCbeta), a pivotal enzyme in B-cel...
1 Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute...
BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with somatic gain-of-...
The discovery of the JAK2V617F mutation and consti-tutive JAK activation in myeloproliferative neopl...
Todd M Bauer,1,2 Manish R Patel,1,3 Andres Forero-Torres,4 Thomas J George Jr,5 Albert Assad,6 Yinin...
Robyn M Emanuel,1 Holly L Geyer,1 Ruben A Mesa2 1Department of Internal Medicine, 2Department of Hem...
Abstract: Myeloproliferative neoplasms (MPN) are debilitating stem cell-derived clonal myeloid malig...
Mixed phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which a...
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...
BACKGROUND: Dysregulation of the Janus kinase (JAK)/signal transducers and activators of transcripti...
of print at www.jco.org on August 3, 2009. Authors ’ disclosures of potential con-flicts of interest...
Leukemia (2014) 28, 404–407; doi:10.1038/leu.2013.205 Activating point mutations in the JAK2 kinase ...
Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over pla...
JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cyt...
JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cyt...
Item does not contain fulltextBACKGROUND: Protein kinase C beta (PKCbeta), a pivotal enzyme in B-cel...
1 Phase I clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute...
BACKGROUND: Polycythemia vera (PV) is a myeloproliferative neoplasm associated with somatic gain-of-...
The discovery of the JAK2V617F mutation and consti-tutive JAK activation in myeloproliferative neopl...
Todd M Bauer,1,2 Manish R Patel,1,3 Andres Forero-Torres,4 Thomas J George Jr,5 Albert Assad,6 Yinin...
Robyn M Emanuel,1 Holly L Geyer,1 Ruben A Mesa2 1Department of Internal Medicine, 2Department of Hem...
Abstract: Myeloproliferative neoplasms (MPN) are debilitating stem cell-derived clonal myeloid malig...
Mixed phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which a...
Efficacy and mechanism of action of volasertib, a potent and selective inhibitor of Polo-like kinase...
BACKGROUND: Dysregulation of the Janus kinase (JAK)/signal transducers and activators of transcripti...
of print at www.jco.org on August 3, 2009. Authors ’ disclosures of potential con-flicts of interest...
Leukemia (2014) 28, 404–407; doi:10.1038/leu.2013.205 Activating point mutations in the JAK2 kinase ...
Ruxolitinib is a Janus kinase (JAK) (JAK1/JAK2) inhibitor that has demonstrated superiority over pla...
JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cyt...
JAK2 constitutive activation/overexpression is common in classical Hodgkin lymphoma, and several cyt...
Item does not contain fulltextBACKGROUND: Protein kinase C beta (PKCbeta), a pivotal enzyme in B-cel...